Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
Date:11/6/2012

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2012.

"Our positive results from a second Phase 2 study of telotristat etiprate provide further evidence of its potential to benefit patients with carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "The initiation of a registrational Phase 3 study of telotristat etiprate in carcinoid syndrome patients represents another significant milestone in the advancement of Lexicon's clinical pipeline."

Key Progress

  • Lexicon is proceeding with preparations for the initiation of Phase 3 studies of LX4211, an oral, dual inhibitor of sodium glucose transporters 1 and 2, in type 2 diabetes and a Phase 2 clinical trial of LX4211 in type 1 diabetes. 
  • In October 2012, Lexicon announced positive top-line data from an open-label Phase 2 clinical trial of telotristat etiprate (LX1032) in carcinoid syndrome and the initiation of a Phase 3 registrational trial.  Lexicon also continues to enroll patients in a Phase 2 proof-of-concept trial evaluating the effect of telotristat etiprate on symptoms associated with ulcerative colitis.  Telotristat etiprate is an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.
  • Lexicon continues to enroll patients with diarrhea-predominant irritable bowel syndrome (IBS-d) in a Phase 2 trial of LX1033, an inhibit
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon to Provide Third Quarter 2012 Financial Results
    2. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    3. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    4. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    5. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    6. Lexicon to Provide Second Quarter 2012 Financial Results
    7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    8. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    9. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
    10. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
    11. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... 2015  In recognition of Rare Disease Day and ... bleeding disorders community, CSL Behring announced today ... of protein therapies to the World Federation of Hemophilia ... has worked to improve the lives of people with ... the WFH,s Global Alliance for Progress (GAP) Program aimed ...
    (Date:2/27/2015)... 27, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today announced ... Conference on Tuesday, March 10, 2015. Rob Kill ... Chief Financial Officer, will present at 4:00 p.m. Pacific ... the conference at the Ritz Carlton in ...
    (Date:2/26/2015)... , February 27, 2015 ... 2014 market research report to its store. This ... Ulcers, therapeutic pipeline. The report "Corneal ... the therapeutic development for Corneal Ulcers. Corneal Ulcers ... includes bacterial infections, viral infections & fungal infections. ...
    Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5
    ... 2011 Rcadia Medical Imaging has achieved proof-of-concept with ... directly from a coronary CT angiography (cCTA) study. This ... standard, Agatston scoring, has the potential to eliminate the ... thereby reduce costs  and decrease patient radiation exposure. This ...
    ... 14, 2011 PAREXEL International Corporation (NASDAQ: PRXL ... Fiscal Year 2011 on Tuesday, August 9, 2011 after the ... on PAREXEL,s website at www.PAREXEL.com and on the ... will host a conference call and live webcast at 10:00 ...
    Cached Medicine Technology:Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call 2
    (Date:2/27/2015)... UT (PRWEB) February 27, 2015 ... Worst Commuter Cities in Florida " report today. ... from the 2013 U.S. Census Bureau survey, considering ... the time of the survey. , The report ... including methods of commuting and a breakdown of ...
    (Date:2/27/2015)... February 27, 2015 With support from Google, ... Days at MoMath, a new collaboration offering Title I schools ... math museum in North America on ten days over the ... grades 6-8 from seven schools in the Bronx and Queens ... learning. , MoMath strives to fulfill the incredible demand for ...
    (Date:2/27/2015)... February 27, 2015 The decision to relocate ... newer facilities and to make camp more accessible to campers ... for a Contact Football Camp. The fields are in premier ... the country,” states Mike de Surville, vice president of US ... comprised of experienced coaches with the passion to create a ...
    (Date:2/27/2015)... With Spring’s wet weather on the way, it is important ... in mind. The latest article from Clean Crawls ... space conditions and repairs. , Clean Crawls begins their ... as to how water is getting into their crawl spaces. ... is through cracks in the foundation, walls, ceiling, or floor ...
    (Date:2/27/2015)... Oklahoma (PRWEB) February 27, 2015 ... by the U.S. Drug Enforcement Agency (DEA). ... local organizations continue to utilize the “Take-Back” guidelines ... by the FDA. , Eufaula Prescription Drug Disposal ... 1425 Industrial Drive in Eufaula, Oklahoma as the ...
    Breaking Medicine News(10 mins):Health News:40 Best and Worst Commuter Cities in Florida Announced by Obrella 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 3Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:Crawl Space FAQs are Answered in Clean Crawls Latest Article 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3
    ... HealthDay Reporter , TUESDAY, March 13 (HealthDay News) -- The ... like race, age and where they live, and can be ... study. Researchers analyzed food questionnaires from a large group ... the continental United States, with a focus on southeastern states. ...
    ... (March 13, 2012) Scientists have identified a new compound ... common form of liver cancer and fifth most common ... Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene ... Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth ...
    ... , SATURDAY, March 10 (HealthDay News) -- ... last long after typical head injury symptoms disappear, researchers ... link to physical function could help improve treatment for ... the University of Kentucky, who led the study as ...
    ... (HealthDay News) -- The drug misoprostol reduced major complications ... a new study. Doctors often use misoprostol for ... now, however, there were no studies large enough to ... complications, either immediate or delayed, according to background information ...
    ... 2012 Research published today in the New England ... for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) ... a strong immune response and a favorable clinical outcome in ... cancer. The size of both the tumor that was ...
    ... Kathleen Doheny HealthDay Reporter , WEDNESDAY, March ... may decrease women,s risk of developing multiple sclerosis. ... of risk [of developing MS symptoms]," said study author ... and research group at Murdoch Children,s Research Institute in ...
    Cached Medicine News:Health News:Race, Location Big Factors in American Diets 2Health News:Race, Location Big Factors in American Diets 3Health News:New compound discovered that rapidly kills liver cancer 2Health News:'Delayed Reactions' May Outlast Other Concussion Effects 2Health News:Drug Reduces Complications in Surgical Abortions: Study 2Health News:NEJM study shows combination treatments benefit melanoma patient 2Health News:Pregnancy May Protect Against MS, Study Says 2
    ... replacement of chordae tendineae is a critical, ... used successfully in chordae tendineae procedures for ... ePTFE, nonabsorbable monofilament suture available with a ... suture also is provided with thin ePTFE ...
    ... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
    ... Grafts have met the challenges of ... for exceptional performance and quality, they ... surgeons worldwide. These grafts require no ... of infection, and ensure utmost thrombectomy ...
    ... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
    Medicine Products: